Journal of clinical & experimental oncology最新文献

{"title":"Prognostic Implications of Hyaluronic Acid Binding Protein 1 (HABP1) Expression, Estrogen Receptor (ER) and Progesterone Receptor (PR) Loss in Endometrial Carcinoma","authors":"O. Harb, M. Elfeky, O. Elfarargy, Rham Z. Ahmed, S. Balata, A. Alnemr","doi":"10.4172/2324-9110.1000199","DOIUrl":"https://doi.org/10.4172/2324-9110.1000199","url":null,"abstract":"Background: Endometrial carcinoma (EC) is the 4th commonest female cancer and the commonest gynecological tract malignancy. The prevalence rate is increasing; mainly in developing countries and the prognosis for recurrent or advanced EC are poor. The 5-year survival rates of EC patients are poor especially in women with metastatic EC. These bad outcomes need novel prognostic and predictive markers for EC for better managements of patients. Hyaluronic acid binding protein 1 (HABP1), which has a specific affinity toward hyaluronan (HA), was primarily discovered in cervical carcinoma (HeLa) cells. It is a eukaryotic protein conserved and ubiquitously found in multiple organisms; yeasts and humans. HABP1 expression, clinicopathological and prognostic importance in endometrial carcinoma is still not sufficiently clarified. Estrogen Receptor (ER) and Progesterone Receptor (PR) are biological molecules that have been studied as prognostic markers because of their essential physiological rules. Molecular biology advancements allow introduction of these hormone receptors to expect outcome of many cancers, e.g. ovarian, breast and EC. \u0000Aim: The aim of that study was to explore the expressions of HABP1, ER and PR in endometrial carcinoma patients, correlating their expressions with clinic-pathological factors and prognosis of patients. \u0000Methods: HABP1, ER and PR expressions were evaluated in sections from 60 paraffin blocks of EC. We analyzed correlations between the levels of markers expressions and prognosis of our patients. \u0000Results: HABP1 was expressed in 61% of EC. ER and PR were high in 56% and 63% of the patients, respectively. HABP1 expression, ER and PR loss were significantly associated with disease progression, disease free survival and poor overall survival (p=0.001, p=0.001and p=0.001, respectively). \u0000Conclusion: HABP1 high expression with ER and PR loss are markers of poor pognosis of EC patients.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42807875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tongue Reconstruction with Submental Flap: An Observational Study","authors":"A. Kushwaha","doi":"10.4172/2324-9110.1000195","DOIUrl":"https://doi.org/10.4172/2324-9110.1000195","url":null,"abstract":"Objective: Successful tongue reconstruction should restore swallowing, speech function, and cosmesis. This study was done to evaluate the functional outcomes of tongue reconstruction using submental flap for tongue defects. \u0000Method: From August 2016 to June 2017, patients receiving submental flap for tongue reconstruction were included in the study. All patients had class II defect after surgery. Speech intelligibility score and swallowing assessment were done for functional evaluation. \u0000Results: Total seven patients underwent submental flap reconstruction for tongue defect during the study period. Speech intelligibility assessment showed good outcome in 5 and acceptable outcome in 2 patients. Swallowing assessment showed good MTF score in 6 and acceptable score in 1 patient. There was no local recurrence. \u0000Conclusion: Submental flap is good alternative for tongue reconstruction in patient with class II defects after surgical resection.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45873223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post Mastectomy Pain Syndrome- Role of Preservation of Intercostobrachial Nerve: A Retrospective Analysis in Breast Cancer Patients in Jharkhand","authors":"A. Kushwaha, T. Kumar","doi":"10.4172/2324-9110.1000196","DOIUrl":"https://doi.org/10.4172/2324-9110.1000196","url":null,"abstract":"Background: Post mastectomy pain syndrome is experienced by 20 to 30 % patient after breast surgery. Sectioning of the intercostobrachial nerve during breast surgeries is thought to be dominant cause this chronic neuropathic pain. We evaluate the role of preservation of intercostobrachial nerve in post mastectomy pain syndrome. \u0000Method: Twenty patients were retrospectively divided into two groups. 08 patients in group A underwent preservation of intercostobrachial nerve and in Group B which included 12 patients nerve was sectioned. Pain assessment was done subjectively on 3 months and 6 months post-operatively by visual analogue scale. \u0000Results: The average time taken for surgery in group a patient was 90 minutes and in group B was 82 minutes. The BMI was also slightly higher in group B patients. Difference in pain score was not stastically significant at the end of three months (p=0.052); however the difference in pain score was stastically significant at the end of 6 months (p=0.027) between the groups. \u0000Conclusion: Preservation of intercostobrachial nerve prevents post mastectomy pain syndrome; however larger randomized studies are required for further verification of results.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45792481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expressions of Orphan Nuclear Receptor TR3/Nur77 in Chronic Hepatopathy and Its Clinical Significance.","authors":"Yingling Zeng,&nbsp;Xiaoguang Ye,&nbsp;Degui Liao,&nbsp;Shizhang Huang,&nbsp;Huinan Mao,&nbsp;Dezheng Zhao,&nbsp;Huiyan Zeng","doi":"10.4172/2324-9110.1000188","DOIUrl":"https://doi.org/10.4172/2324-9110.1000188","url":null,"abstract":"<p><strong>Objective: </strong>Although great success has been achieved in cancer treatment, current cancer therapies, including anti-tumorigenesis and anti-angiogenesis, still face the problems of insufficient efficacy, resistance and intrinsic refractoriness, in addition to their toxic side effects. There is a demand to identify additional targets that can be blocked to turn off the downstream effects of most, if not all, pathways. Our studies suggest that orphan nuclear receptor TR3 (human)/Nur77 (mouse) is such a target. Most recently, we reported that TR3/Nur77 expression in human hepatic cancer tissues correlates well with tumor progress, suggesting that TR3 is a specific therapeutic target for hepatic cancers. However, the correlation of TR3/Nur77 expression in hepatocellular carcinoma (HCC) with chronic hepatitis has not been studied.</p><p><strong>Methods: </strong>The expression of TR3/Nur77 was analyzed in human primary hepatic cancer specimens from patients that have complete medical records with Immunohistochemically staining. The statistical analysis was used to access the significance of TR3 expression in tumor tissues, cirrhosis tissues and chronic hepatitis tissues with and without hepatitis B virus infection (HBV(+) and HBV(-)), which were obtained from para-tumor tissues.</p><p><strong>Results: </strong>The positive rates of TR3/Nur77 expression in hepatocellular carcinoma, cancerous liver cirrhosis and chronic hepatitis are 66.67%, 30%, and 20%, respectively, which are statistic significant (p<0.05). The positive rates of TR3/Nur77 expression in hepatocellular carcinoma are statistic significant (p<0.05) with 81.25% and 20% in HBV (+) or HBV (-), respectively.</p><p><strong>Conclusion: </strong>The positive expression rate of TR3/Nur77 in hepatocellular carcinoma is higher than that in chronic hepatitis and cirrhosis. The positive rate of TR3/Nur77 expression in hepatocellular carcinoma is higher with HBV infection than that without infection. Our results suggest that TR3/Nur77 plays an important role in the progression of chronic hepatitis, and the occurrence and development of HCC.</p>","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573240/pdf/nihms895577.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9938530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Pharmacological Modulation of Ca2+/Camp Intracellular Signaling Pathways and Traditional Antitumoral Pharmaceuticals: A Plausible Multi-target Combined Therapy?","authors":"P. Errante, S. Francisco, ro Menezes-Rodrigues, A. Caricati‐Neto, Le, ro Bueno Bergantin","doi":"10.4172/2324-9110.1000e111","DOIUrl":"https://doi.org/10.4172/2324-9110.1000e111","url":null,"abstract":"Cancer is a major public health issue worldwide, affecting both developed and developing countries, thus leading to the rise of a large annual expenses every fiscal year. Surgery, radiotherapy, chemotherapy, immunotherapy and multitarget pharmaceutical therapies are the current strategies for cancer treatment. Generally, cancer treatments are based on the clinical history of the patients, including histological type and the presence of molecular biomarkers. Nonetheless, new options are clearly needed to increase survival and improve the patients’ quality of life, especially for those in advanced stages of this disease. Thus, the increased knowledge of the mechanisms responsible for growth, invasion and metastasis of cancer, including development of intrinsic resistance, is critical.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70249918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rho-Kinases in Oral Squamous Cell Carcinoma: A Review","authors":"Anjali P Ganjre, S. Sangamithra, Asmita Kharche","doi":"10.4172/2324-9110.1000189","DOIUrl":"https://doi.org/10.4172/2324-9110.1000189","url":null,"abstract":"OSCC is most common and lethal malignancy worldwide. Global estimated death is to be more than 10,000 annually. Metastasis is the deadly consequence associated with OSCC because of homing of cancer cells to lymph nodes. Motility of cells is accomplished by important signaling molecule known as Rho kinases. Rhokinases modulates cytoskeleton of “transformed” malignant cell to govern distant metastasis. Interaction of Rho kinases and signaling molecules assists in driving the tumor cell through extracellular matrix and blood vessels to reach the destined location. By focusing and systemizing on the molecular aspect of Rhokinases will help in divulging the problem of the mobility of OSCC cells and will also aid in designing novel anticancer therapies.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45265012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of NAD (P) H-Quinone Oxidoreductase 1 (NQO1) On Cancer Progression and Chemoresistance","authors":"Pimradasiri Srijiwangsa, K. Na-Bangchang","doi":"10.4172/2324-9110.1000192","DOIUrl":"https://doi.org/10.4172/2324-9110.1000192","url":null,"abstract":"NAD(P)H-Quinone Oxidoreductase 1 (NQO1), originally referred to as DT-diaphorase, is a xenobiotic metabolizing/antioxidant enzyme that detoxifies chemical stressors, providing cytoprotection in normal tissues. NQO1 catalyzes obligatory two-electron reduction of several endogenous and environmental quinones to hydroquinone that are ready for further conjugation and excretion. The enzyme requires NADH or NADPH as an electron donor for enzymatic activity. High-level of NQO1 expression has however, been correlated with numerous human malignancies, suggesting its role in cancer progression and chemoresistance. This adaptation renders the cancer cells to survive in relatively high oxidative stress condition compared to normal cells, as well as protects cancer cells from toxic action of chemotherapeutic agents. Inhibitors of NQO1 enzyme have been found to improve anticancer activities of conventional chemotherapeutic agents. The review provides a perspective on a molecular basis of NQO1-mediated cancer cells progression and the suppression and possible strategy to improve chemosensitivity and to overcome chemoresistance of NQO1 inhibitors when used in combination with chemotherapeutic drugs.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42160772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-Irradiated Fibroblasts Influence the Chemosensitivity of Co-Cultivated Squamous Cell Carcinoma Cells","authors":"Gehrke T, Scherzad A, Hackenberg S, Ickrath P, Schendzielorz P, Hagen R, Kleinsasser N","doi":"10.4172/2324-9110.1000178","DOIUrl":"https://doi.org/10.4172/2324-9110.1000178","url":null,"abstract":"Objective: Tumor stroma mainly consists of fibroblasts, which have a multitude of interactions with the cancer cells they surround. Since irradiation and chemotherapy are common therapeutic options for squamous cell carcinoma of the head and neck, the effects of irradiation on tumor stroma and their sensitivity to chemotherapeutic agents are of significant therapeutic interest. \u0000Methods: FaDu head and neck squamous cell carcinoma cells (HNSCC) were cultivated with fibroblasts from pre-irradiated and non-irradiated human skin for 24 hours. Then the co-cultures were treated with either Cisplatin, Paclitaxel or 5-Fluorouracil for 48 hours. Analysis of tumor viability and apoptosis were conducted via the MTT assay and the Annexin V-propidium iodide test. Secretion of interleukin-8 (IL-8) was analyzed with an enzyme-linked immunosorbent assay. \u0000Results: Co-cultures with pre-irradiated fibroblasts showed decreased viability, higher rates of apoptosis and necrosis, and lower levels of IL-8 as compared to co-cultures with non-irradiated fibroblasts in the presence of chemotherapeutic agents as well as in the control group. \u0000Conclusion: We therefore postulate an influence of a previous irradiation of fibroblasts on the chemosensitivity of co-cultured tumor cells. To achieve a better understanding of the effects of cytostatic treatment in pre-irradiated head and neck cancer patients, further investigations are warranted.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43810018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of Circulating Mir-206 in Patients with Lung and Head and Neck Cancers and its Association with Cancer Cachexia","authors":"N. Sut, Yo, R. Hariani, P. Wuyung, A. Rahmadi, A. Mulawarman, C. Herawati, R. Ramli","doi":"10.4172/2324-9110.1000191","DOIUrl":"https://doi.org/10.4172/2324-9110.1000191","url":null,"abstract":"Background: cancer cachexia is a common problem found in advanced stage cases. Pathophysiology of cachexia is complicated, involving cytokines and regulator molecules such as microRNA (miRNA). MiR-206, a specific miRNA in skeletal muscle cells was thought to play important role in regulating skeletal muscle loss but have not been studied well in cachectic patients. \u0000Objective: to evaluate the clinical significance of circulating miR-206 in cancer patients presenting with cancer cachexia. \u0000Method: A cross-sectional study was performed in Dharmais Cancer Hospital, Jakarta between September and December 2015. Patients enrolled were lung and head and neck cancers. Cachexia was defined as body mass index less than 20 kg/m2. MiR-206 expression was assayed using quantitative real-time polymerase chain reaction (RT-PCR), whereas miR-16 served as internal control. The results were expressed as cycle threshold (CT) and fold change (FC) which was calculated using the 2-ΔΔCT method. \u0000Results: Seventy patients were enrolled during the study period; consisting 37 (52.9%) lung 33 (47.1%) head and neck cancers. There were 31 (41.3%) patients presenting with cachexia. Serum miR-206 was overexpressed in cancer patients compare to normal healthy subjects. MicroRNA-206 expression was slightly up-regulated in cachectic patients than non-cachectic patients, i.e. FC=1.355 in lung cancers and FC=1.438 in head and neck cancers. \u0000Conclusion: Circulating miR-206 is overexpressed advanced stage lung cancer as well as head and neck cancer patients. Increased circulating miR-206 in cachectic patients may reflect extensive skeletal muscle loss associated with cancer cachexia.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48966242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing Gefitinib and Erlotinib With Regard To Brain Metastases Recurrence in EGFR-Mutant Non-Small Cell Lung Cancer Patients","authors":"K. Nakahama, A. Tamiya, Y. Taniguchi, Yoko Naoki, M. Kanazu, S. Atagi","doi":"10.4172/2324-9110.1000190","DOIUrl":"https://doi.org/10.4172/2324-9110.1000190","url":null,"abstract":"Brain metastases of lung cancer are associated with a poor prognosis. Little research has been conducted to directly compare erlotinib with gefitinib regarding the frequency of central nerve system recurrence. This is the first study to directly compare erlotinib with gefitinib in terms of brain metastases recurrence rates in patients with EGFR-mutant NSCLC who had no brain metastasis at the time of starting TKI treatment. This was a single-center retrospective study. Advanced or recurrent non-small cell lung cancer patients with no brain metastases at the time of starting initial tyrosine kinase inhibitor treatment who received either gefitinib or erlotinib monotherapy were selected. The primary endpoint was the incidence of brain metastases, and secondary endpoints included the objective response rate, progression-free survival, overall survival, and Post-Progression Survival in subgroups based on tyrosine kinase inhibitor treatment and the occurrence of brain metastases. There were 119 patients in the gefitinib group and 13 patients in the erlotinib group. Brain metastases at disease progression were observed in 16 patients in the gefitinib group, and in no patients in the erlotinib group (13.5% vs. 0%, p=0.37). The median overall survival was 29.2 months in the gefitinib group and was not reached in the erlotinib group (p=0.14). The median PPS was 15.5 months in the gefitinib group and 23.7 months in the erlotinib group (p=0.11). Based on the occurrence of brain metastases, Post-Progression Survival was significantly longer in the no brain metastases group (8.0 months vs. 17.9 months, p=0.01). These data showed the possibility of a lower central-nerve-system recurrence rate with erlotinib compared with gefitinib. Post-Progression Survival in patients with brain metastases was significantly shorter than that of patients without brain metastases.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48364245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}